79 related articles for article (PubMed ID: 24398383)
21. Exploiting the Achilles heel of cancer: the therapeutic potential of poly(ADP-ribose) polymerase inhibitors in BRCA2-defective cancer.
Kyle S; Thomas HD; Mitchell J; Curtin NJ
Br J Radiol; 2008 Oct; 81 Spec No 1():S6-11. PubMed ID: 18820000
[TBL] [Abstract][Full Text] [Related]
22. The emerging potential of poly(ADP-ribose) polymerase inhibitors in the treatment of breast cancer.
Drew Y; Plummer R
Curr Opin Obstet Gynecol; 2010 Feb; 22(1):67-71. PubMed ID: 19934756
[TBL] [Abstract][Full Text] [Related]
23. Design, synthesis and biological evaluation of novel imidazo[4,5-c]pyridinecarboxamide derivatives as PARP-1 inhibitors.
Zhu Q; Wang X; Chu Z; He G; Dong G; Xu Y
Bioorg Med Chem Lett; 2013 Apr; 23(7):1993-6. PubMed ID: 23481647
[TBL] [Abstract][Full Text] [Related]
24. PARP inhibition restores extrinsic apoptotic sensitivity in glioblastoma.
Karpel-Massler G; Pareja F; Aimé P; Shu C; Chau L; Westhoff MA; Halatsch ME; Crary JF; Canoll P; Siegelin MD
PLoS One; 2014; 9(12):e114583. PubMed ID: 25531448
[TBL] [Abstract][Full Text] [Related]
25. PARP inhibitors in BRCA1-/BRCA2-associated and triple-negative breast cancers.
Stebbing J; Ellis P; Tutt A
Future Oncol; 2010 Apr; 6(4):485-6. PubMed ID: 20373860
[No Abstract] [Full Text] [Related]
26. Niraparib: A Poly(ADP-ribose) Polymerase (PARP) Inhibitor for the Treatment of Tumors with Defective Homologous Recombination.
Jones P; Wilcoxen K; Rowley M; Toniatti C
J Med Chem; 2015 Apr; 58(8):3302-14. PubMed ID: 25761096
[TBL] [Abstract][Full Text] [Related]
27. Curcumin suppresses multiple DNA damage response pathways and has potency as a sensitizer to PARP inhibitor.
Ogiwara H; Ui A; Shiotani B; Zou L; Yasui A; Kohno T
Carcinogenesis; 2013 Nov; 34(11):2486-97. PubMed ID: 23825154
[TBL] [Abstract][Full Text] [Related]
28. Therapeutic potential of poly(ADP-ribose) polymerase inhibitor AG014699 in human cancers with mutated or methylated BRCA1 or BRCA2.
Drew Y; Mulligan EA; Vong WT; Thomas HD; Kahn S; Kyle S; Mukhopadhyay A; Los G; Hostomsky Z; Plummer ER; Edmondson RJ; Curtin NJ
J Natl Cancer Inst; 2011 Feb; 103(4):334-46. PubMed ID: 21183737
[TBL] [Abstract][Full Text] [Related]
29. Functional ex vivo assay to select homologous recombination-deficient breast tumors for PARP inhibitor treatment.
Naipal KA; Verkaik NS; Ameziane N; van Deurzen CH; Ter Brugge P; Meijers M; Sieuwerts AM; Martens JW; O'Connor MJ; Vrieling H; Hoeijmakers JH; Jonkers J; Kanaar R; de Winter JP; Vreeswijk MP; Jager A; van Gent DC
Clin Cancer Res; 2014 Sep; 20(18):4816-26. PubMed ID: 24963051
[TBL] [Abstract][Full Text] [Related]
30. Major contribution of the multidrug transporter P-glycoprotein to reduced susceptibility of poly(ADP-ribose) polymerase-1 knock-out cells to doxorubicin action.
Wesierska-Gadek J
J Cell Biochem; 2005 Aug; 95(5):1012-28. PubMed ID: 15861398
[TBL] [Abstract][Full Text] [Related]
31. Cisplatin resistance associated with PARP hyperactivation.
Michels J; Vitale I; Galluzzi L; Adam J; Olaussen KA; Kepp O; Senovilla L; Talhaoui I; Guegan J; Enot DP; Talbot M; Robin A; Girard P; Oréar C; Lissa D; Sukkurwala AQ; Garcia P; Behnam-Motlagh P; Kohno K; Wu GS; Brenner C; Dessen P; Saparbaev M; Soria JC; Castedo M; Kroemer G
Cancer Res; 2013 Apr; 73(7):2271-80. PubMed ID: 23554447
[TBL] [Abstract][Full Text] [Related]
32. PARP inhibitors: new partners in the therapy of cancer and inflammatory diseases.
Peralta-Leal A; Rodríguez-Vargas JM; Aguilar-Quesada R; Rodríguez MI; Linares JL; de Almodóvar MR; Oliver FJ
Free Radic Biol Med; 2009 Jul; 47(1):13-26. PubMed ID: 19362586
[TBL] [Abstract][Full Text] [Related]
33. PARP inhibition induces BAX/BAK-independent synthetic lethality of BRCA1-deficient non-small cell lung cancer.
Paul I; Savage KI; Blayney JK; Lamers E; Gately K; Kerr K; Sheaff M; Arthur K; Richard DJ; Hamilton PW; James JA; O'Byrne KJ; Harkin DP; Quinn JE; Fennell DA
J Pathol; 2011 Aug; 224(4):564-74. PubMed ID: 21706479
[TBL] [Abstract][Full Text] [Related]
34. Platinated benzonaphthyridone is a stronger inhibitor of poly(ADP-ribose) polymerase-1 and a more potent anticancer agent than is the parent inhibitor.
Wang B; Qian H; Yiu SM; Sun J; Zhu G
Eur J Med Chem; 2014 Jan; 71():366-73. PubMed ID: 24361480
[TBL] [Abstract][Full Text] [Related]
35. PARP inhibitors: will the new class of drugs match the hype?
Tuma RS
J Natl Cancer Inst; 2009 Sep; 101(18):1230-2. PubMed ID: 19738163
[No Abstract] [Full Text] [Related]
36. Inhibition of poly(ADP-ribose) polymerase-1 enhances temozolomide and topotecan activity against childhood neuroblastoma.
Daniel RA; Rozanska AL; Thomas HD; Mulligan EA; Drew Y; Castelbuono DJ; Hostomsky Z; Plummer ER; Boddy AV; Tweddle DA; Curtin NJ; Clifford SC
Clin Cancer Res; 2009 Feb; 15(4):1241-9. PubMed ID: 19174487
[TBL] [Abstract][Full Text] [Related]
37. Structure-activity relationships for substituted bis(acridine-4-carboxamides): a new class of anticancer agents.
Gamage SA; Spicer JA; Atwell GJ; Finlay GJ; Baguley BC; Denny WA
J Med Chem; 1999 Jul; 42(13):2383-93. PubMed ID: 10395479
[TBL] [Abstract][Full Text] [Related]
38. PARP inhibitors: polypharmacology versus selective inhibition.
Ekblad T; Camaioni E; Schüler H; Macchiarulo A
FEBS J; 2013 Aug; 280(15):3563-75. PubMed ID: 23601167
[TBL] [Abstract][Full Text] [Related]
39. A novel class of substituted spiro [quinazoline-2,1'-cyclohexane] derivatives as effective PPAR-1 inhibitors: molecular modeling, synthesis, cytotoxic and enzyme assay evaluation.
Amin KM; Anwar MM; Syam YM; Khedr MA; Kamel MM; Kassem EM
Acta Pol Pharm; 2013; 70(4):687-708. PubMed ID: 23923393
[TBL] [Abstract][Full Text] [Related]
40. APTO-253 Is a New Addition to the Repertoire of Drugs that Can Exploit DNA BRCA1/2 Deficiency.
Tsai CY; Sun S; Zhang H; Local A; Su Y; Gross LA; Rice WG; Howell SB
Mol Cancer Ther; 2018 Jun; 17(6):1167-1176. PubMed ID: 29626126
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
